Forum Financial Management LP Acquires 37,820 Shares of Pfizer Inc. $PFE

Forum Financial Management LP raised its holdings in Pfizer Inc. (NYSE:PFE) by 47.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 117,904 shares of the biopharmaceutical company’s stock after buying an additional 37,820 shares during the period. Forum Financial Management LP’s holdings in Pfizer were worth $3,004,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PFE. Curio Wealth LLC increased its position in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $30,000. Finally, True Wealth Design LLC boosted its holdings in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7%

Shares of PFE opened at $25.48 on Friday. The firm has a market cap of $144.84 billion, a P/E ratio of 14.81 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The firm’s 50-day simple moving average is $25.26 and its 200 day simple moving average is $24.95.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Morgan Stanley cut their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $27.88.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 data for a PADCEV + Keytruda bladder‑cancer combo bolsters Pfizer’s oncology franchise and revenue outlook; clinical validation can drive upside for PFE if regulatory and commercial plans follow. Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment
• Positive Sentiment: Real‑world breast cancer study update signals Pfizer is pushing strategically in the HER2‑positive space — a reminder of ongoing pipeline commercialization opportunities beyond legacy products. Pfizer’s Real‑World Breast Cancer Study Signals Strategic Push in HER2-Positive Market
• Positive Sentiment: Coverage of Pfizer’s AI and precision‑oncology deals highlights a shift in the investment story toward higher‑growth, tech‑enabled oncology programs — can improve long‑term growth perception. How Pfizer’s AI and Precision Oncology Deals Have Changed Its Investment Story
• Positive Sentiment: Partnership with Gordian Bio to probe new obesity targets strengthens Pfizer’s exposure to the high‑growth weight‑loss drug market — a strategic priority highlighted in recent sector narratives. Pfizer partners Gordian Bio to probe new obesity targets
• Positive Sentiment: Broader healthcare sector rebound (VHT coverage) is attracting flows to undervalued pharma names like Pfizer, supporting multiple expansion and demand for dividend/defensive stocks. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: JPMorgan Healthcare Conference preview: JPM will likely produce company updates and M&A headlines that can move PFE intraday — a near‑term volatility catalyst but outcome‑dependent. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Unusual options flow: heavy activity in March PFE puts (March 20 $29 put highest Vol/OI) — could reflect hedging or directional bearish bets; watch open interest and dealer delta for short‑term price pressure. Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
• Negative Sentiment: Analyst/retail pieces predicting other healthcare stocks will outperform Pfizer and commentary about a recent ~6% drop signal negative sentiment and may pressure PFE if doubts about growth persist. Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 Pfizer’s Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.